SCHEMBL20726744

SCHEMBL20726744

c1ccc(-c2ccc(-c3nc(-c4ccc5ccc6cccnc6c5n4)nc(-c4ccc5ccc6cccnc6c5n4)n3)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
KDM4E B2RXH2 4/20 0.50
LMNA P02545 4/20 0.50
CCR1 P32246 3/20 0.50
CCR5 P51681 3/20 0.50
CCR8 P51685 3/20 0.50
MMP2 P08253 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
TP53 P04637 2/20 0.50
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GMNN O75496 1/20 0.50
HSP90AA1 P07900 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
MMP9 P14780 1/20 0.50
ALOX15 P16050 1/20 0.50
NFKB1 P19838 1/20 0.50
MMP8 P22894 1/20 0.50
THPO P40225 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20726812 0.97 LMNA (0.53) MAPTKDM4ELMNACCR1CCR5
SCHEMBL26199961 0.94 MAPT (0.50) MAPTKDM4ELMNACCR1CCR5
SCHEMBL19763003 0.94 MAPT (0.50) MAPTKDM4ELMNACCR1CCR5
SCHEMBL19762942 0.94 MAPT (0.50) MAPTKDM4ELMNACCR1CCR5
SCHEMBL20726698 0.94 MAPT (0.50) MAPTKDM4ELMNACCR1CCR5
SCHEMBL24608612 0.93 KDM4E (0.43) MAPTKDM4ELMNACCR1CCR5
SCHEMBL23600052 0.92 MAPT (0.52) MAPTKDM4ELMNACCR1CCR5
SCHEMBL20726792 0.92 MAPT (0.52) MAPTKDM4ELMNACCR1CCR5
SCHEMBL25844938 0.90 CCR1 (0.46) MAPTKDM4ELMNACCR1CCR5
SCHEMBL20726728 0.90 CYP17A1 (0.46) MAPTKDM4ELMNACCR1CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200095224-A1 NITROGEN HETEROCYCLIC COMPOUND, DISPLAY PANEL AND DISPLAY APPARATUS WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) 2020-03-26 US disclosed
US-20190051841-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2019-02-14 US disclosed
EP-3441391-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME Samsung Display Co., Ltd. (KR) 2019-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190051841-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AOC2, CYP1A1, CRY1 MAPT 2986/4885KDM4E 4165/4885LMNA 638/4885
US-20200095224-A1 NITROGEN HETEROCYCLIC COMPOUND, DISPLAY PANEL AND DISPLAY APPARATUS C5, CCND2, OCIAD2 MAPT 3533/4885KDM4E 3483/4885LMNA 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.